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Several cell types secrete small membranous vesicles that contain cell-speciﬁc collections of pro-
teins, lipids, and genetic material. The function of these vesicles is to allow cell-to-cell signaling
and the horizontal transfer of their cargo molecules. Here, we demonstrate that muscle cells secrete
nano-sized vesicles and that their release increases during muscle differentiation. Analysis of these
nanovesicles allowed us to characterize them as exosome-like particles and to deﬁne the potential
role of the multifunctional protein Alix in their biogenesis.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Animal cells release nano-sized single membrane vesicles that
function in signaling and the horizontal transfer of their cargo
molecules (proteins, mRNAs, and microRNAs) to other cells [1–3].
Research on extracellular nanovesicles has focused primarily on
the immune system and tumor cells. Recently, it has also been re-
ported that a skeletal muscle cell line (C2C12) can release vesicles
[4]; however, how muscle cells generate these vesicles and what
their effectors are remain largely unknown.
Alix is an evolutionarily conserved adaptor protein that has
been implicated in cytoskeleton and membrane remodeling
[5–7]. In line with these reports, we have recently shown that Alix
also plays a part in actin cytoskeleton remodeling in muscle cells,
and that the Ozz-E3 ubiquitin ligase is crucial for the regulation
of this function of Alix [8]. In addition, it has been suggested that,
because Alix can interact with both a lipid and proteins and retainsa characteristic ‘‘banana-shaped’’ structure, it can generate or scaf-
fold a negative curvature within the membrane as part of the in-
ward budding process within the endocytic pathway [9,10]. An
interplay between F-actin and membrane-bending proteins like
Alix is thought to occur, in order to promote a negative curvature
of the membrane during processes such as ﬁlopodia formation,
vesicle budding and midbody abscission. In fact, we and others
have demonstrated that Alix downregulation leads to a decrease
in the number of late endosomes and muscle podia, and to altera-
tions in their composition [7,8]; thus, Alix loss of function may
interfere with mechanisms that regulate membrane dynamics.
Here, we demonstrate that differentiated muscle cells release
nanovesicles extracellularly and that the loss of Alix alters the bud-
ding and composition of these vesicles.
2. Materials and methods
2.1. Antibodies and reagents
Commercial antibodies included mouse anti-AIP1/Alix for
immunoblotting (BD Transduction Labs) and anti-Alix (Santa Cruz
Biotechnology) for immunogold electron microscopy, alpha-eno-
lase (Santa Cruz Biotechnology), anti-CD63 (Santa Cruz Biotechnol-
ogy), anti-Hsp70/Hsc70 (Novus Biologicals), anti-Elongin C (BD
Biosciences), anti-MyHc (MF20, Developmental Studies Hybridoma
Fig. 1. Muscle cells release nanovesicles. (A) Electron microscope analyses of 3D
cultures of differentiating C2C12 cells show the presence of outward budding
intermediates (nascent vesicles) at the plasma membrane with an average diameter
of 80 nm (scale bar = 100 nm). (B) Transmission electron microscopy shows
immunogold labeling of Alix in the nanovesicles from 3D cultures of differentiated
C2C12 myotubes (10 nm gold particles). Left panel shows a nascent nanovesicle,
right panel shows a released vesicle (PM = plasma membrane, ECM = extra-cellular
matrix) (scale bar = 100 nm).
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(Santa Cruz Biotechnology), anti-Bcl-2 (Calbiochem), anti-Bax
(Calbiochem), anti-PARP (Cell Signaling Technology). Rabbit anti-
Ozz antibody was prepared as described [11].
siRNAs targeting Alix and standard negative controls, and the
transfection reagent were purchased from Dharmacon, as reported
[8].
2.2. Cell culture methods
For three-dimensional cultures, C2C12 were cultured as
reported [8]. Primary myoblast cultures were established as
described previously [11].
2.3. Puriﬁcation of nanovesicles by differential ultracentrifugation
Nanovesicles were isolated and quantiﬁed according to a previ-
ously published method [12]. This isolation method included a
penultimate centrifugation step (10,000g for 30 min) that al-
lowed the removal of small cell debris and larger microvesicles
for the subsequent pelleting of nanovesicles, comprised mainly of
exosomes [13]. After washing, the pellet is resuspended either in
RIPA buffer or 4% PFA, for further immunoblot or electron micro-
scope analyses, respectively. To have an estimation of the amount
of secreted nanovesicles, we quantiﬁed and compared the total
protein content of the vesicle lysates using the Bradford assay [12].
2.4. Electron microscope analysis and immunogold labeling of muscle-
derived nanovesicles
Nanovesicle pellets ﬁxed in 4% PFA were mounted on Formvar–
carbon coated EM gold grids by layering 10-ll drops of vesicle
preparations, and letting grids air dry. Grid-mounted preparations
were stained with uranyl acetate and lead citrate, and subse-
quently observed under the JEM-1220 (Jeol) electron microscope
at 120 kV.
Muscle cells were 3D cultured [8] and inserts were ﬁxed in PFA
4%. Inserts were then dehydrated in alcohol and embedded in liquid
LRWhiteMedium Grade Resin before inclusion in gelatine capsules
(EMS). Samples were then cut into 70 nm-thick ultrathin sections
and layered onto Formvar coated gold grids (EMS). For immunogold
staining, the grids were rinsed in water, incubated in citrate buffer,
and blocked in 3% BSA-c in T-PBS. Grids were then incubated with
anti-Alix, washed in T-PBS, incubated with AuroProbe EM second-
ary antibody. The grids were post-ﬁxed with 2% glutaraldhyde in
PBS, and contrasted using conventional techniques.3. Results and discussion
3.1. Budding of nanovesicles from the plasma membrane of
differentiated muscle cells
Exosomes are nano-sized (50–100 nm in diameter) membrane-
bound vesicles released by a variety of cell types and speciﬁed by a
plethora of protein markers, including Alix [1–3]. In contrast, micr-
ovesicles tend to constitute a larger and more heterogeneous pop-
ulation of extracellular vesicles, ranging from 50 to 1000 nm in
diameter [14]. Transmission electron microscopy analyses of 3D
cultures of C2C12 myotubes revealed that nanovesicles, ranging
from 50–100 nm and with an average diameter of 80 nm, were re-
leased by direct budding from the plasma membrane (Fig. 1A). 3D
cell cultures exhibit more in vivo-like responses allowing us to
visualize, by immunogold labeling, the distribution of Alix in close
proximity to the surface of budding nanovesicles and decorating
released nanovesicles (Fig. 1B). The size of these muscle-derivedvesicles and the presence of Alix are compatible with what has
been described for exosomes from other cells [12–15].
Together, these observations indicate that skeletal muscle cells
can produce and release nanovesicles directly from the plasma
membrane. This modality of vesicle secretion is consistent with
that previously reported for both microvesicle [16] and nanovesi-
cle biogenesis; in the latter, human CD4+ T cells and certain T cell
lines release nanovesicles—deﬁned as exosomes—directly from
subdomains of their plasma membrane [15,17,18]. However, it
contrasts with the canonical view of exosome release as a delayed
process in which vesicles bud ﬁrst into an intermediate structure,
the multivesicular bodies (MVB), and are subsequently released
upon endosome–plasma membrane fusion [1,3,13]. Nevertheless,
both modes of vesicle secretion involve outward nanovesicle bud-
ding and a negative curvature of specialized endosome-like mem-
branes, either within the MVB or at the plasma membrane [14].
Whether the nanovesicles originating from these two mechanisms
carry the same cargo molecules from the cell and are associated
with the same protein sorting machinery is currently unknown.
In this respect, it is conceivable that Alix, in addition to its canon-
ical involvement in the biogenesis of MVBs and in viral budding,
processes that involve a negative curvature of the membrane,
may also participate in the direct budding of nanovesicles from
the plasma membrane of muscle cells. Supporting this idea, Alix,
which is mainly cytoplasmic, was found associated not only with
actin and the membrane of internal organelles but also with sites
of exosome biogenesis at the plasma membrane of T-cells, together
with other exosomal proteins and the lipid lysobisphosphatidic
acid (LBPA) [6–8,15].
Fig. 2. Characterization of nanovesicles released by differentiated muscle cells. (A) Electron-microscope analysis of whole-mounted vesicles puriﬁed from conditioned-media
(CM) of C2C12 myotubes (DIII) (scale bar = 100 nm). (B)Equal amounts of total proteins (5 lg) extracted from the nanovesicle preparations were immunoblotted for Alix. Alix
is mainly present in the nanovesicle preparation from differentiated muscle cells (DIII). Controls of the procedure show the purity of the nanovesicle preparation. Note, the
10,000g pellets (10Kg), containing cell debris and large microvesicles, were almost negative for Alix. (C) Assessment of myogenic differentiation of C2C12 cells. (Top)
Myoblasts (D0) and myotubes after two (DII), three (DIII) and six days (DVI) of differentiation. (Bottom) Western blots showing the expression of MyHC, myogenin, and MyoD
in lysates of C2C12 cells after the indicated days of differentiation. Ponceau staining is shown as a control of the total protein loaded per lane. (D) Characterization of the
protein content of muscle-released nanovesicles showed the presence of proteins, indicated by gene symbol, that are identiﬁed more often in exosomes of different cell types.
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To further characterize these muscle-released vesicles, we
employed a standard protocol [12] to isolate extracellular nanovesi-cles from larger vesicles (e.g., shedding microvesicles, apoptotic
bodies) using a 24-h culturemedia (CM) of C2C12 and primarymus-
cle cells. In line with the ultrastructural analyses of the nanovesicles
released by the 3D cultures, electron microscopy of negatively
Fig. 3. Alix-depletion affects release and protein content of muscle-derived nanovesicles. (A) Light microscopy analysis (top panel) and transmission electron microscopy
(bottom panel) of 3D cultures of differentiated C2C12 cells (DIII) silenced for Alix showed an altered phenotype. (B) Cytoplasmic (top) and nuclear (bottom) fractions from
Mock- and Alix-silenced myotubes were immunoblotted for the indicated apoptotic markers. Ponceau staining is shown as a control of the total protein loaded per lane. (C)
Treatment of C2C12 myoblast with Alix-speciﬁc double stranded siRNA pools led to a signiﬁcant reduction (80%) in Alix expression compared to mock-transfected cells.
Nanovesicles released by Alix-silenced C2C12 cells exhibited a signiﬁcant accumulation of Hsc70, enolase and actin, and a reduction of CD63.
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ranging in diameter from 50–100 nm (Fig. 2A), a size which is
consistent with the previously characterized ultrastructural mor-
phology of exosomes [12,15]. It is noteworthy that these vesicles
were mainly observed in medium collected from myotubes at DIII
of differentiation, compared to proliferating myoblasts. In addition,
both the total protein content (data not shown) and the amount of
Alix in these vesicle lysateswere signiﬁcantly higher in nanovesicles
released fromdifferentiatedmyotubes than those fromproliferating
myoblasts (Fig. 2B, top panel). Noteworthy, Alix is present in small
amount (CM of C2C12 myotubes) or almost undetectable (CM of
primary myotubes) in the fraction containing small plasma debris
and the largest shedding microvesicles, removed by the 10,000g
centrifugation (10Kg, in Fig. 2B bottom panel).3.3. Characterization of muscle-derived nanovesicles
Dramatic changes occur during myogenesis, and the C2C12 cell
system mimics these events in vitro. Fig. 2C shows the morpholog-
ical and molecular modiﬁcations that distinguish D0-DVI C2C12
muscle cells; we have used MyoD and myogenin as early markers
of muscle differentiation and Myosin Heavy Chain (MyHC) as a
marker of terminal differentiation. Next, we analyzed the protein
contents of these vesicles released by C2C12 muscle cells at these
different days of differentiation (D0, DII, DIII and DVI) by immuno-
blotting, using antibodies speciﬁc for three proteins that, in addi-
tion to Alix, are more often identiﬁed in exosomes of different
cell origin: CD63, enolase, and the Heat shock 70 kDa protein 8
(Hsc70) [3].
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teins showed that the amounts of Alix, Hsc70, and enolase peaked
in vesicles released from differentiated myotubes at DIII (Fig. 2D).
In contrast, the CD63 expression proﬁle was different, as its highest
expression was at DII of differentiation, when many myocytes are
still fusing and the contractile apparatus is being formed (Fig. 2C–
D). This result suggests that the nanovesicles produced by
myoblasts (D0), myocytes (DI-DII), and myotubes (DIII) could differ
in their protein content as a result of a different biogenesis/func-
tion of the extracellular vesicles during myogenesis. This ﬁnding
is in line with recent data showing that distinct populations of
exosomes (apical and basolateral exosomes) from the same cell
population do exist, and that CD63 is the marker for only one of
them [19].
We have shown previously that, in muscle cells, Alix is one of
the substrates of the RING-type ubiquitin ligase, Ozz-E3 [8]. This li-
gase complex includes the substrate-recognition module Ozz, as
well as Elongin B and C, Rbx1 and Cullin 5 [11]. We have also
shown that Ozz-E3 plays an active role in muscle differentiation
and homeostasis, by targeting and ubiquitinating selective
substrates associated with the actin cytoskeleton [8,11,20]. We
therefore tested whether Ozz and Elongin C were present in the
muscle-derived nanovesicles. We detected Ozz and Elongin C
exclusively in nanovesicles released by differentiated muscle cells
at DIII (Fig. 2C). This result is particularly relevant in view of the
fact that the ubiquitin pathway plays a crucial role in the mem-
brane trafﬁcking and actin remodeling processes. Overall our anal-
yses showed that the muscle-derived nanovesicles, depleted of
larger microvesicles, were positive for components of the ubiquiti-
nation pathway and for all the exosomal markers tested. These
data, together with the ﬁndings that the muscle-derived extracel-
lular vesicles are homogenous in size and shape, allowed us to con-
clude that our preparation of nanovesicles is mainly composed of
exosome-like particles.
3.4. Effect of Alix loss of function on the muscle cell release of
nanovesicles
Finally, we investigated the role of Alix in the biogenesis of the
muscle-released vesicles by analyzing 3D-cultured C2C12 cells in
which Alix expression was silenced by siRNAs. Downregulation
of Alix, obtained using two independent siRNA pools with different
sequences, was speciﬁc and effective, as we routinely obtained 70–
90% knockdown of Alix expression compared to mock-transfected
cells (Fig. 3B, left panel). The viability and morphology of the cells
treated with two different non-targeting siRNA pools were compa-
rable to those of the mock-transfected cells that served as negative
control (data not shown). Light microscopy analysis of semithin
sections of 3D muscle cell inserts showed that Alix-silenced cells
had an altered morphology, displaying extensive membrane bud-
ding of enlarged vesicles compared to controls (Fig. 3A). The extra-
cellular vesicles released by Alix-silenced myotubes were
heterogeneous in size, ranging from 70–200 nm, and were irregu-
larly shaped (Fig. 3A). We can exclude that these aberrant vesicles
were merely the result of Alix-induced apoptotic events for several
reasons: they were smaller than apoptotic bodies (usually 500–
2000 nm); we have never observed any apoptotic nuclear changes
in Alix-silenced cells [8]; and the level of apoptosis markers such as
nuclear PARP, Bcl-2, and Bax did not change between Alix- and
mock-silenced myotubes (Fig. 3B). The plasma membrane alter-
ation of the Alix-silenced extracellular vesicles was in line with
previous reports [8,20–22], suggesting that Alix has a primary role
in regulating membrane dynamics in muscle cells not only in the
formation of ﬁlopodia [8] but also in the biogenesis of muscle-re-
leased vesicles. This was further explored by analyzing the protein
composition of the nanovesicles puriﬁed from the 2D culture ofC2C12 myotubes (DIII) after knockdown of Alix. We recovered
the same amount of total proteins from the nanovesicles released
by mock- and Alix-silenced cells. However, immunoblot analysis
of equal protein amounts of the nanovesicle proteins showed that
the downregulation of Alix led to a signiﬁcant accumulation of the
cytoplasmic proteins Hsc70, enolase and actin, and a reduction of
the endosome/exosome associated protein CD63 in the nanovesi-
cles released from Alix-silenced myotubes, compared to mock-
transfected myotubes (Fig. 3C). We hypothesize that loss of Alix
leads to deregulated budding and/or scission of vesicles from the
plasma membrane. This effect can culminate in vesicles abnor-
mally loaded with cargos of cytoplasmic origin (increased level of
Hsc70, enolase and actin). CD63, like Alix, has been detected in
the endosome-like domains of the plasma membrane [14], and
its decrease in the Alix-depleted nanovesicles suggests that these
membrane domains may not be well structured and are not in-
volved in the biogenesis of the abnormal vesicles from the Alix-si-
lenced myotubes. Altogether, our ﬁndings highlight the role of Alix
in modulating the proper biogenesis of a major class of muscle-re-
leased nanovesicles, the loading of these vesicles with speciﬁc car-
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